Predictors for symptom re-exacerbation after targeted stepwise drug discontinuation in first-episode schizophrenia. Results of the first-episode study within the German research network on schizophrenia

Schizophrenia Research

Volumn 170, Issue 1, 2016, Pages 168-176

  Gaebel, Wolfgang ^a   Riesbeck, Mathias ^a   Wölwer, Wolfgang ^a   Klimke, Ansgar ^a,b   Eickhoff, Matthias ^a,c   von Wilmsdorff, Martina ^a   de Millas, Walter ^d   Maier, Wolfgang ^e   Ruhrmann, Stephan ^f   Falkai, Peter ^g,h   Sauer, Heinrich ⁱ   Schmitt, Andrea ^h,j   Riedel, Michael ^h,k   Klingberg, Stefan ^l   Möller, Hans Jürgen ^h  

^a Department of Orthopedic Surgery   (Germany)

^b Department of Psychiatry and Psychotherapy ^*  (Germany)

^c Department of Psychiatry   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e UNIVERSITY OF BONN   (Germany)

^f UNIVERSITY OF COLOGNE   (Germany)

^g UNIVERSITY OF GÖTTINGEN   (Germany)

^h UNIVERSITY OF MUNICH   (Germany)

ⁱ JENA UNIVERSITY HOSPITAL   (Germany)

^j UNIVERSITY OF HEIDELBERG   (Germany)

^k Vinzenz von Paul Hospital   (Germany)

^l UNIVERSITY OF TÜBINGEN   (Germany)

more..

Author keywords

Drug discontinuation; First episode; Predictors; Schizophrenia; Symptom re exacerbation

Indexed keywords

CLOZAPINE; HALOPERIDOL; OLANZAPINE; RISPERIDONE; ZIPRASIDONE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG INDICATION; DRUG INTERMITTENT THERAPY; DRUG RESPONSE; FEASIBILITY STUDY; FEMALE; HIGH RISK POPULATION; HUMAN; MAINTENANCE THERAPY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; PREDICTION; PRIORITY JOURNAL; RECURRENT DISEASE; RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA; SCORING SYSTEM; TREATMENT DURATION; YOUNG ADULT; ACUTE DISEASE; GERMANY; MEDICATION COMPLIANCE; MULTIVARIATE ANALYSIS; PROGNOSIS; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL;

ACUTE DISEASE; ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; GERMANY; HUMANS; LOGISTIC MODELS; MALE; MEDICATION ADHERENCE; MULTIVARIATE ANALYSIS; PROGNOSIS; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA;

EID: 84947601395     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2015.10.024     Document Type: Article

References (55)

1. Addington D., Addington J., Schissel B. A depression rating scale for schizophrenics. Schizophr. Res. 1990, 3:247-251.
2. American Psychiatric Association (APA) Practice guideline for the treatment of patients with schizophrenia, second edition. Am. J. Psychiatry 2004, 161(Suppl.):1-56.
3. American Psychiatric Association (APA) Social and Occupational Functioning Assessment Scale (SOFAS). Diagnostic and Statistical Manual of Mental Disorders 2000, 817-818. American Psychiatric Association, Washington, DC. fourth edition (text revision).
4. Andreasen N.C., Carpenter W.T., Kane J.M., Lasser R.A., Marder S.R., Weinberger D.R. Remission in schizophrenia: proposed criteria and rationale for consensus. Am. J. Psychiatry 2005, 62:441-449.
5. Andreasen N.C. Negative symptoms in schizophrenia. Arch. Gen. Psychiatry 1982, 39:784-788.
6. Ascher-Svanum H., Zhu B., Faries D.E., Salkever D., Slade E.P., Peng X., Conley R.R. The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry 2010, 10(2). http://www.biomedcentral.com/1471-244X/10/2.
7. Boonstra G., Burger H., Grobbee D.E., Kahn R.S. Antipsychotic prophylaxis is needed after remission from a first psychotic episode in schizophrenia patients: results from an aborted randomised trial. Int. J. Psychiatry Clin. Pract. 2011, 15(2):128-134.
8. Carpenter W.T., Buchanan R.W., Kirkpatrick B., Breier A.F. Diazepam treatment of early signs of exacerbation in schizophrenia. Am. J. Psychiatry 1999, 156:299-303.
9. Chen E.Y., Hui C.L., Lam M.M., Chiu C.P., Law C.W., Chung D.W., Tso S., Pang E.P., Chan K.T., Wong Y.C., Mo F.Y., Chan K.P., Yao T.J., Hung S.F., Honer W.G. Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial. BMJ 2010, 19(341):c4024.
10. Chouinard G. Severe cases of neuroleptic-induced supersensitivity psychosis. Diagnostic criteria for the disorder and its treatment. Schizophr. Res. 1991, 5:21-33.
11. Csernansky J.G., Mahmoud R., Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N. Engl. J. Med. 2002, 346:16-22.
12. Emsley R., Chiliza B., Asmal L. The evidence for illness progression after relapse in schizophrenia. Schizophr. Res. 2013, 148:117-121.
13. Fitzgerald P., de Castella A., Arya D., Simons W.R., Eggleston A., Meere S., Kulkarni J. The cost of relapse in schizophrenia and schizoaffective disorder. Australas. Psychiatry 2009, 17:265-272.
14. Fleischhacker W., Bergmann K., Perovich R. The hillside akathisia scale (HAS): a new rating instrument for neuroleptic-induced akathisia. Psychopharmacol. Bull. 1989, 25:222-226.
15. Frances A., Pincus H.A., First M.B. The Global Assessment of Functioning Scale (GAF). Diagnostic and Statistical Manual of Mental Disorders 1994, 32. American Psychiatric Association, Washington, DC. Fourth Edition.
16. Gaebel W., Jänner M., Frommann N., Pietzcker A., Köpcke W., Linden M., Müller P., Müller-Spahn F., Tegeler J. First vs. multiple episode schizophrenia: two-year outcome of intermittent and maintenance medication strategies. Schizophr. Res. 2002, 53:145-159.
17. Gaebel W., Riesbeck M. Revisiting the relapse predictive validity of prodromal symptoms in schizophrenia. Schizophr. Res. 2007, 95:19-29.
18. Gaebel W., Riesbeck M. Are there clinically useful predictors and early warning signs for pending relapse?. Schizophr. Res. 2014, 152:469-477.
19. Gaebel W., Riesbeck M., von Wilmsdorff M., Burns T., Derks E.M., Kahn R.S., Rössler W., Fleischhacker W.W., EUFEST Study Group Drug attitude as predictor for effectiveness in first-episode schizophrenia: results of an open randomized trial (EUFEST). Eur. Neuropsychopharmacol. 2010, 20:310-316.
20. Gaebel W., Riesbeck M., Wobrock T. Schizophrenia guidelines across the world: a selective review and comparison. Int. Rev. Psychiatry 2011, 23:379-387.
21. Gaebel W., Riesbeck M., Wölwer W., Klimke A., Eickhoff M., von Wilmsdorff M., Heuser I., Maier W., Klosterkötter J., Falkai P., Schlösser R., Schmitt A., Riedel M., Klingberg S., Köpcke W., Ohmann C., Möller H.J. Rates and predictors of remission in first-episode schizophrenia within 1 year of antipsychotic maintenance treatment. Results of a randomized controlled trial within the German Research Network on Schizophrenia. Schizophr. Res. 2014, 152:478-486.
22. Gaebel W., Riesbeck M., Wölwer W., Klimke A., Eickhoff M., von Wilmsdorff M., Jockers-Scherübl M.C., Kühn K., Lemke M., Bechdolf A., Bender S., Degner D., Schlösser R., Schmidt L.G., Schmitt A., Jäger M., Buchkremer G., Falkai P., Klingberg S., Köpcke W., Maier W., Häfner H., Ohmann C., Salize H.J., Schneider F., Möller H.J. Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia. One-year results of a randomized controlled trial within the German Research Network on Schizophrenia. J. Clin. Psychiatry 2007, 68(11):1763-1774.
23. Gaebel W., Riesbeck M., Wölwer W., Klimke A., Eickhoff M., von Wilmsdorff M., Lemke M., Heuser I., Maier W., Huff W., Schmitt A., Sauer H., Riedel M., Klingberg S., Köpcke W., Ohmann C., Möller H.J., German Study Group on First-Episode Schizophrenia Relapse prevention in first-episode schizophrenia: maintenance vs. intermittent drug treatment with prodrome-based early intervention. Results of a randomized controlled trial within the German research network on schizophrenia. J. Clin. Psychiatry 2011, 72:205-218.
24. Goldman H.H., Skodol A.E., Lave T.R. Revising axis V for DSM-IV. A review of measures of social functioning. Am. J. Psychiatry 1992, 149:1148-1156.
25. Abnormal Involuntary Movement Scale (AIMS). ECDEU Assessment Manual for Psychopharmacology, Revised 1976, 534-537. US Dept Health, Education and Welfare, Washington, DC. W. Guy (Ed.).
26. Clinical Global Impressions (CGI) Scale. ECDEU Assessment Manual for Psychopharmacology, Revised 1976, 218-222. US Dept Health, Education, and Welfare, Washington, DC. W. Guy (Ed.).
27. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 1960, 23:56-62.
28. Hogan T.P., Awad A.G., Eastwood R.A. Self-report predictive of drug compliance in schizophrenia: reliability and discriminative ability. Psychol. Med. 1983, 13:177-183.
29. Hong J., Windmeijer F., Novick D., Haro J.M., Brown J. The cost of relapse in patients with schizophrenia in the European SOHO (schizophrenia outpatient health outcomes) study. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2009, 33:835-841.
30. Hui C.L., Wong G.H., Tang J.Y., Chang W.C., Chan S.K., Lee E.H., Lam M.M., Chiu C.P., Law C.W., Chung D.W., Tso S., Pang E.P., Chan K.T., Wong Y.C., Mo F.Y., Chan K.P., Hung S.F., Honer W.G., Chen E.Y. Predicting 1-year risk for relapse in patients who have discontinued or continued quetiapine after remission from first-episode psychosis. Schizophr. Res. 2013, 150:297-302.
31. Kane J.M. Schizophrenia. N. Engl. J. Med. 1996, 334:34-41.
32. Kane J.M. Treatment strategies to prevent relapse and encourage remission. J. Clin. Psychiatry 2007, 68(Suppl. 14):27-30.
33. Kay S.R., Opler L.A., Fiszbein A. The positive and negative syndrome scale (PANSS) rating manual. Soc. Behav. Sci. Doc. 1986, 17:28-29.
34. Kemp R., David A. Psychological predictors of insight and compliance in psychotic patients. Br. J. Psychiatry 1996, 169:444-450.
35. Klingberg S., Schneider S., Conradt B., Schaub A., Wagner M., Wölwer W., Bechdolf A., Gaebel W., Buchkremer G. Individual psychological intervention for relapse prevention in post acute, first episode schizophrenia-2-year follow-up of a multicentric randomized clinical trial 2015, (in preparation).
36. Lacro J.P., Dunn L.B., Dolder C.R., Leckband S.G., Jeste D.V. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J. Clin. Psychiatry 2002, 63:892-909.
37. Leucht S., Tardy M., Komossa K., Heres S., Kissling W., Salanti G., Davis J.M. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 2012, 379:2063-2071.
38. Lieberman J.A., Perkins D., Belger A., Chakos M., Jarskog F., Boteva K., Gilmore J. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol. Psychiatry 2001, 50:884-897.
39. Marder S.R., Davis J.M., Chouinard G.J. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the north American trials. Clin. Psychol. 1997, 58:538-546.
40. McGorry P., Alvarez-Jimenez M., Killackey E. Antipsychotic medication during the critical period following remission from first-episode psychosis: less is more. JAMA Psychiatry 2013, 70:898-900.
41. Möller H.J., Riedel M., Jäger M., Wickelmaier F., Maier W., Kühn K.U., Buchkremer G., Heuser I., Klosterkötter J., Gastpar M., Braus D.F., Schlösser R., Schneider F., Ohmann C., Riesbeck M., Gaebel W. Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German research network on schizophrenia. Int. J. Neuropsychopharmacol. 2008, 11:985-997.
42. Moncrieff J. Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. Acta Psychiatr. Scand. 2006, 114:3-13.
43. Müller M.J., Marx-Dannigkeit P., Schlösser R., Wetzel H., Addington D., Benkert O. The Calgary depression rating scale for schizophrenia: development and interrater reliability of a German version (CDSS-G). J. Psychiatr. Res. 1999, 33:433-443.
44. Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int. Clin. Psychopharmacol. 1995, 10(Suppl. 3):133-138.
45. National Institute for Health and Care Excellence (NICE) Psychosis and schizophrenia in adults: treatment and management. NICE Clinical Guideline 178 2014, http://www.guidance.nice.org.uk/cg178.
46. Nuechterlein K.H., Dawson M.E. A heuristic vulnerability/stress model of schizophrenic episodes. Schizophr. Bull. 1984, 10:300-312.
47. Sampson S., Mansour M., Maayan N., Soares-Weiser K., Adams C.E. Intermittent drug techniques for schizophrenia. Cochrane Database Syst. Rev. 2013, 20:7.
48. Scandinavian Society of Psychopharmacology Committee of Clinical Investigations (UKU) The UKU Side Effect Rating Scale: scale for the registration of unwanted effects of psychotropics. Acta Psychiatr. Scand. 1987, 76(334, Suppl.):81-94.
49. Simpson G.M., Angus J.W. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. Suppl. 1970, 212:11-19.
50. Undurraga J., Murru A., Vieta E. Early medication discontinuation on long-term recovery outcome in first-episode psychosis. JAMA Psychiatry 2014, 71:206-207.
51. Wölwer W., Buchkremer G., Häfner H., Klosterkötter J., Maier W., Möller H.J., Gaebel W. German research network on schizophrenia-bridging the gap between research and care. Eur. Arch. Psychiatry Clin. Neurosci. 2003, 253:321-329.
52. World Health Organization (WHO) International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) 1992, World Health Organization, Geneva, Switzerland.
53. Wunderink L., Nieboer R.M., Wiersma D., Sytema S., Nienhuis F.J. Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial. JAMA Psychiatry 2013, 70:913-920.
54. Wunderink L., Nienhuis F.J., Sytema S., Slooff C.J., Knegtering R., Wiersma D. Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome. J. Clin. Psychiatry 2007, 68:654-661.
55. Zipursky R.B., Menezes N.M., Streiner D.L. Risk of symptom recurrence with medication discontinuation in first-episode psychosis: a systematic review. Schizophr. Res. 2014, 152:408-414.